MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Sialorrhea"

  • 2022 International Congress

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges & Ghent, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC) into…
  • 2022 International Congress

    Comparison of Voice, Speech, Swallowing and Drooling Problems in Parkinson’s Disease Patients with Healthy Individuals

    M. Sapmaz Atalar, G. Genç, ş. Oğur (Istanbul, Turkey)

    Objective: To compare voice, speech, swallowing and drooling problems in Parkinson's disease (PD) patients with healthy individuals (HI) by using objective and subjective methods and…
  • MDS Virtual Congress 2021

    Efficacy of Incobotulinumtoxin/A Treatment for Children/Adolescents with Sialorrhea associated with Neurological Disorders

    S. Berweck, H. Kim, M. Banach, A. Hanschmann, M. Althaus, M. Bonikowski (Vogtareuth, Germany)

    Objective: The SIPEXI (Sialorrhea Pediatric Xeomin Investigation) study investigated efficacy and safety of intraglandular incobotulinumtoxinA (incoBoNT/A) injections in children/adolescents with sialorrhea associated with neurological disorders…
  • MDS Virtual Congress 2020

    Prevalence, impact, and factors associated with excessive buccal saliva in the COPARK database

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, M. Fabbri, W. Meissner, A. Rachdi, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To describe the prevalence of sialorrhea and drooling in Parkinson’s Disease (PD) patients of the COPARK study, to find factors associated to these conditions,…
  • MDS Virtual Congress 2020

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study

    B. Bergmans, V. Schotte, N. Sys, E. Van Massenhove, M. Van Zandijcke (Brugge, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…
  • 2019 International Congress

    Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

    L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)

    Objective: To assess the onset of action for rimabotulinumtoxinBinjections in the salivary glands for the treatment of sialorrhea. Background: Sialorrhea (drooling) causes significant morbidity including impaired oral…
  • 2019 International Congress

    Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea

    K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa (Boca Raton, FL, USA)

    Objective: To assess the safety, tolerability and effectiveness of repeated rimabotulinumtoxinB injections in adults with troublesome sialorrhea over a period of 1 year. Background: Sialorrhea…
  • 2019 International Congress

    RimbotulinumtoxinB in the treatment of adult sialorrhea

    S. Isaacson, W. Ondo, M. Lew, K. Dashtipour, D. Chary, T. Clinch, F. Pagan (Boca Raton, FL, USA)

    Objective: To assess efficacy, safety and tolerability of repeat injections of rimabotulinumtoxinBfor the treatment of sialorrhea. Background: Sialorrhea (drooling) can cause significant morbidity in several neurological disorders,…
  • 2019 International Congress

    Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea

    S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch (Boca Raton, FL, USA)

    Objective: To assess the duration of rimabotulinumtoxinB action in the management of sialorrhea. Background: In neurological disorders, sialorrhea (drooling) is both prevalent and problematic. Local…
  • 2019 International Congress

    GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease

    T. Mestre, E. Freitas, M. Lopez, A. Basndwah, L. de Oliveira, D. Al-Shorafat, Z. Alarfaz, H. Shinawi, S. Reddie, D. Mancini, J. Lui, D. Grimes, S. Fox (Ottawa, ON, Canada)

    Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley